Adjuvant Iodine¹³¹ Lipiodol after Resection of Hepatocellular Carcinoma

Table 1

Patient characteristics.

	Surgery only	Surgery + I^131-lipiodol	Significance ( value)
Number	52	58
Age, mean and SD	58 (14)	55 (12)	0.23
Sex, (M/F)	36/16	44/14	0.29
AJCC (2010) stage,
1	23	32	0.34
2	14	17	0.83
3a	9	5	0.25
3b	1	2	1.0
3c	5	2	0.25
Tumor size (mm), median and range	46.5 (15–150)	35.0 (15–110)	0.55
Resection margin (mm), median and range	5.5 (0.050–43)	5 (0.10–45)	0.81
Multifocality,	20	15	0.22
Microvascular invasion,	18	19	0.50
Major vascular invasion,	2	2
Differentiation,
Well	10	11	1.0
Moderate	32	33	0.70
Poor	9	14	0.35
Not stated/unknown	1	0	0.47
Race,
Asian	28	40	0.042
Caucasian	20	14	0.15
Other	4	4	1.0
Chronic liver disease,
Hepatitis B	27	34	0.57
Hepatitis C	11	16	0.51
Other	14	8	0.10
Child-Pugh stage,
A	51	58	0.47
B	1	0
Cirrhosis,	26	31	0.43
Serum AFP, median and range	10.75 (0–13241)	28 (1–7281)	0.39